- Home
- AVDL vs RERE Comparison
AVDL vs RERE Comparison
Compare AVDL & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDL
- RERE
- Stock Information
- Founded
- AVDL 2015
- RERE 2011
- Country
- AVDL Ireland
- RERE China
- Employees
- AVDL N/A
- RERE N/A
- Industry
- AVDL Biotechnology: Pharmaceutical Preparations
- RERE Other Specialty Stores
- Sector
- AVDL Health Care
- RERE Consumer Discretionary
- Exchange
- AVDL Nasdaq
- RERE Nasdaq
- Market Cap
- AVDL 764.3M
- RERE 678.4M
- IPO Year
- AVDL 1996
- RERE 2021
- Fundamental
- Price
- AVDL $7.91
- RERE $3.37
- Analyst Decision
- AVDL Strong Buy
- RERE
- Analyst Count
- AVDL 7
- RERE 0
- Target Price
- AVDL $18.86
- RERE N/A
- AVG Volume (30 Days)
- AVDL 1.5M
- RERE 899.4K
- Earning Date
- AVDL 03-03-2025
- RERE 03-11-2025
- Dividend Yield
- AVDL N/A
- RERE N/A
- EPS Growth
- AVDL N/A
- RERE N/A
- EPS
- AVDL N/A
- RERE N/A
- Revenue
- AVDL $169,117,000.00
- RERE $2,188,701,829.00
- Revenue This Year
- AVDL $51.49
- RERE $28.08
- Revenue Next Year
- AVDL $32.18
- RERE $25.05
- P/E Ratio
- AVDL N/A
- RERE N/A
- Revenue Growth
- AVDL 504.79
- RERE 27.16
- 52 Week Low
- AVDL $7.39
- RERE $1.13
- 52 Week High
- AVDL $19.09
- RERE $3.70
- Technical
- Relative Strength Index (RSI)
- AVDL 43.28
- RERE 63.85
- Support Level
- AVDL $7.45
- RERE $2.66
- Resistance Level
- AVDL $7.97
- RERE $3.16
- Average True Range (ATR)
- AVDL 0.37
- RERE 0.19
- MACD
- AVDL -0.01
- RERE 0.04
- Stochastic Oscillator
- AVDL 33.82
- RERE 89.87
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.